Head-To-Head Contrast: Compass Therapeutics (NASDAQ:CMPX) and AVAX Technologies (OTCMKTS:AVXT)

AVAX Technologies (OTCMKTS:AVXT) and Compass Therapeutics (NASDAQ:CMPX) are both medical companies, but which is the better investment? We will compare the two companies based on the strength of their profitability, earnings, risk, analyst recommendations, institutional ownership, dividends and valuation.

Analyst Recommendations

This is a summary of recent ratings and recommmendations for AVAX Technologies and Compass Therapeutics, as reported by MarketBeat.com.

	Sell Ratings	Hold Ratings	Buy Ratings	Strong Buy Ratings	Rating Score
AVAX Technologies	0	0	0	0	0.00
Compass Therapeutics	1	1	11	1	2.86

Compass Therapeutics has a consensus target price of $12.91, suggesting a potential upside of 526.65%. Given Compass Therapeutics’ stronger consensus rating and higher possible upside, analysts clearly believe Compass Therapeutics is more favorable than AVAX Technologies.

Institutional and Insider Ownership

68.4% of Compass Therapeutics shares are owned by institutional investors. 6.0% of AVAX Technologies shares are owned by insiders. Comparatively, 18.7% of Compass Therapeutics shares are owned by insiders. Strong institutional ownership is an indication that endowments, large money managers and hedge funds believe a company will outperform the market over the long term.

Valuation & Earnings

This table compares AVAX Technologies and Compass Therapeutics”s revenue, earnings per share (EPS) and valuation.

	Gross Revenue	Price/Sales Ratio	Net Income	Earnings Per Share	Price/Earnings Ratio
AVAX Technologies	N/A	N/A	N/A	N/A	N/A
Compass Therapeutics	$850,000.00	436.45	-$66.49 million	($0.41)	-5.02

AVAX Technologies has higher earnings, but lower revenue than Compass Therapeutics.

Profitability

This table compares AVAX Technologies and Compass Therapeutics’ net margins, return on equity and return on assets.

	Net Margins	Return on Equity	Return on Assets
AVAX Technologies	N/A	N/A	N/A
Compass Therapeutics	N/A	-39.75%	-35.29%

Summary

Compass Therapeutics beats AVAX Technologies on 7 of the 9 factors compared between the two stocks.

About AVAX Technologies

AVAX Technologies, Inc., a development stage biopharmaceutical company, develops autologous cell vaccine technologies for the treatment of cancer. The company’s product candidates that have completed phase II clinical trials include M-VAX for the treatment of melanoma and O-VAX for the treatment for ovarian cancer. It also develops LungVax for the treatment of non-small cell lung cancer. The company was formerly known as Walden Laboratories, Inc. and changed its name to AVAX Technologies, Inc. in March 1996. AVAX Technologies, Inc. was founded in 1990 and is based in Philadelphia, Pennsylvania.

About Compass Therapeutics

Compass Therapeutics, Inc., a clinical-stage oncology-focused biopharmaceutical company, engages in developing antibody-based therapeutics to treat various human diseases in the United States. The company's lead product candidates include CTX-009, a bispecific antibody that blocks Delta-like ligand 4 a ligand of Notch-1, and vascular endothelial growth factor A signaling pathways, which are critical to angiogenesis and tumor vascularization; and CTX-471, an IgG4 monoclonal antibody that is an agonist of CD137, a key co-stimulatory receptor on immune cells. It also develops CTX-8371, a bispecific inhibitor that targets PD-1 and PD-L1 checkpoint inhibitor antibodies. The company was founded in 2014 and is headquartered in Boston, Massachusetts.